In the late 1990s, the use of targeted therapy against KIT variations with imatinib marked a new era in GIST treatment and ushered in precision oncological treatment for all solid malignant tumors.1 Although treatment of advanced GIST with imatinib achieved sustained objective responses, primary and acquired secondary resistance to imatinib remains a clinical challenge.2 In the setting of imatinib failure, newer generations of tyrosine kinase inhibitors have shown efficacy as second-line (ie, sunitinib) and third-line (ie, regorafenib) agents.3,4. Here, KIT is linked to gastrointestinal stromal tumor.